Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES KEVIN MCCLOSKEY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1992951149
CMS profile
648059
Location
HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$607,387.08

407 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 7 of 9; records 301–350 of 407 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES KEVIN MCCLOSKEY

NPI 1992951149 · CMS profile ID 648059

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 9; records 301–350 of 407 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992951149?year=2025&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 407 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992951149?year=2025&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 407 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992951149?year=2025&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 9; records 301–350 of 407 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992951149?year=2025&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

407 matching records · $607,387.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 407 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–350 of 407.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Geron Corporation $1,600.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891210 CMS
Geron Corporation $4,000.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891212 CMS
Geron Corporation $4,000.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891214 CMS
Geron Corporation $134.2004/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238891216 CMS
GlaxoSmithKline, LLC. $225.0404/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190455044 CMS
GlaxoSmithKline, LLC. $301.7004/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190588188 CMS
GlaxoSmithKline, LLC. $117.4804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191141806 CMS
GlaxoSmithKline, LLC. $960.5604/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191654119 CMS
GlaxoSmithKline, LLC. $3,200.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190455399 CMS
GlaxoSmithKline, LLC. $6,400.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190687167 CMS
GlaxoSmithKline, LLC. $120.9204/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190703302 CMS
GlaxoSmithKline, LLC. $3,200.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190754892 CMS
GlaxoSmithKline, LLC. $241.8304/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190832876 CMS
GlaxoSmithKline, LLC. $4,800.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190902169 CMS
Incyte Corporation $342.5004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225990471 CMS
Blueprint Medicines Corporation $1,474.0004/02/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1235815136 CMS
Syndax Pharmaceuticals, Inc. $387.4803/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238993118 CMS
Syndax Pharmaceuticals, Inc. $5,600.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238993120 CMS
Geron Corporation $4,000.0003/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238891206 CMS
GlaxoSmithKline, LLC. $1,497.2803/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190655532 CMS
GlaxoSmithKline, LLC. $421.8303/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190680259 CMS
Geron Corporation $914.6503/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238891204 CMS
GlaxoSmithKline, LLC. $785.3103/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191184767 CMS
Syndax Pharmaceuticals, Inc. $5,600.0003/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238993112 CMS
Syndax Pharmaceuticals, Inc. $4,400.0003/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238993114 CMS
Syndax Pharmaceuticals, Inc. $205.4203/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238993116 CMS
Takeda Pharmaceuticals U.S.A., Inc. $480.8503/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1223780058 CMS
Geron Corporation $4,800.0003/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891202 CMS
GlaxoSmithKline, LLC. $125.0003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190968551 CMS
GlaxoSmithKline, LLC. $636.9803/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191310473 CMS
SERVIER PHARMACEUTICALS LLC $18.1603/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229099715 CMS
GlaxoSmithKline, LLC. $125.0003/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190761188 CMS
Incyte Corporation $2,740.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225991671 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,400.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223779922 CMS
Geron Corporation $16.1403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238891194 CMS
Geron Corporation $1,600.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891196 CMS
Geron Corporation $1,600.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891198 CMS
Geron Corporation $1,600.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238891200 CMS
PharmaEssentia USA Corporation $1,340.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1246827621 CMS
PharmaEssentia USA Corporation $1,675.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1246827627 CMS
Syndax Pharmaceuticals, Inc. $987.4403/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238993108 CMS
Syndax Pharmaceuticals, Inc. $124.9903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238993110 CMS
Incyte Corporation $125.5603/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225991697 CMS
ABBVIE INC. $16.3903/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203046254 CMS
Syndax Pharmaceuticals, Inc. $386.9603/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238993106 CMS
SOBI, INC $409.2703/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240289462 CMS
SOBI, INC $6,160.0003/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240289466 CMS
SOBI, INC $124.9903/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240289470 CMS
SOBI, INC $230.1003/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240289475 CMS
SOBI, INC $870.9803/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240289480 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $339,648.15 309
PY2020 $240,495.10 149
PY2021 $192,837.00 147
PY2022 $383,379.37 268
PY2023 $426,468.49 307
PY2024 $615,903.99 426
PY2025 $607,387.08 407

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,470,967.33 1,676
PY2024 Principal investigator $762,085.86 415
PY2023 Principal investigator $2,162,906.61 182
PY2022 Principal investigator $2,026,330.52 185
PY2021 Recipient $4,442.10 1
PY2021 Principal investigator $4,208,118.88 127
PY2020 Recipient $8,925.50 1
PY2020 Principal investigator $991,151.35 80
PY2019 Recipient $15,053.40 1
PY2019 Principal investigator $702,962.50 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,676 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,800.00 12/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417137
Principal investigator 1 TAIHO ONCOLOGY, INC. $11,416.81 12/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418529
Principal investigator 1 Servier BioInnovation $2,252.25 12/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965338
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 12/11/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609393
Principal investigator 1 Sumitomo Pharma America, Inc. $200.00 12/11/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609397
Principal investigator 1 Daiichi Sankyo Inc. $2,250.00 12/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350122
Principal investigator 1 Servier BioInnovation $551.00 12/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965336
Principal investigator 1 TAIHO ONCOLOGY, INC. $45,977.61 12/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414983
Principal investigator 1 Stemline Therapeutics Inc. $842.00 12/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104154
Principal investigator 1 Stemline Therapeutics Inc. $3,004.00 12/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104167
Principal investigator 1 TAIHO ONCOLOGY, INC. $15,827.22 12/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417827
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 12/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418539
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 12/03/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663491
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,378.75 12/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419239
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,855.24 12/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211414981
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349920
Principal investigator 1 Daiichi Sankyo Inc. $8.85 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349930
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349936
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349940
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349944
Principal investigator 1 Daiichi Sankyo Inc. $8.85 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349968
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349982
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349988
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349998
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350008
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350014
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350020
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350022
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350032
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350044
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350052
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350062
Principal investigator 1 Daiichi Sankyo Inc. $8.85 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350066
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350074
Principal investigator 1 Daiichi Sankyo Inc. $62.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350076
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350080
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350096
Principal investigator 1 Daiichi Sankyo Inc. $62.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350100
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350118
Principal investigator 1 Daiichi Sankyo Inc. $8.85 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350136
Principal investigator 1 Daiichi Sankyo Inc. $26.55 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350138
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350156
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350178
Principal investigator 1 Ionis Pharmaceuticals, Inc. $270.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782119
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,455.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782123
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608456
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608459
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608463
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608466
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608471
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608476
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608480
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608483
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608487
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608491
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608495
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608498
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608501
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608504
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608508
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608512
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608516
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608520
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608524
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608527
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608531
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608536
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608540
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608544
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608548
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608551
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608555
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608559
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608562
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608567
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608570
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608573
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608578
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608582
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608584
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608588
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608591
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608596
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608599
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608603
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608607
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608610
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608612
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608615
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608619
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608622
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608626
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608630
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608634
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608638
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608642
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608646
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608650
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608653
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608657
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608660
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608663
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608666
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608671
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608677
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608681
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608684
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608688
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608692
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608696
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608698
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608701
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608705
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608709
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608714
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608717
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608721
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608725
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608729
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608731
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608734
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608738
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608742
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608745
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608749
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608753
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608758
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608763
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608766
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608770
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608775
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608779
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608783
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608787
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608792
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608795
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608799
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608804
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608809
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608813
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608819
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608823
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608827
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608830
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608834
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608837
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608842
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608846
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608849
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608853
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608856
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608860
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608864
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608868
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608874
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608878
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608882
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608885
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608889
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608893
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608896
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608900
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608904
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608907
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608911
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608915
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608919
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608923
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608927
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608931
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608936
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608941
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608944
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608948
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608950
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608954
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608959
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608964
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608968
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608972
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608975
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608979
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608984
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608988
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608993
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608997
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609001
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609004
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609008
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609012
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609016
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609020
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609024
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609028
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609033
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609036
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609040
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609044
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609048
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609052
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609056
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609060
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609065
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609069
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609073
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609076
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609080
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609084
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609088
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609092
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609095
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609098
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609101
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609105
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609109
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609113
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609117
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609120
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609125
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609129
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609133
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609137
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609140
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609145
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609147
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609152
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609156
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609161
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609164
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609169
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609172
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609176
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609181
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609184
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609188
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609191
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609197
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609200
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609203
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609208
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609212
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609215
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609219
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609223
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609226
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609230
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609234
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609237
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609240
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609244
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609248
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609251
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609254
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609258
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609261
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609265
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609268
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609272
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609276
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609279
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609282
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609286
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609290
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609294
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609299
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609302
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609306
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609310
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609313
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609317
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609320
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609323
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609327
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609331
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609334
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609339
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609342
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609347
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609351
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609355
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609358
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609362
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609367
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609371
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609374
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609379
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609382
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609386
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176609389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,669.10 11/27/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 1223266529
Principal investigator 1 Daiichi Sankyo Inc. $2,750.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349914
Principal investigator 1 Daiichi Sankyo Inc. $250.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350172
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,122.20 11/21/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782114
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,357.12 11/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418527
Principal investigator 1 Genmab U.S., Inc. $2,750.00 11/13/2025 Covered Recipient Teaching Hospital
Jfk University Medical Center
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235923888
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349896
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349898
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349904
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349908
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349924
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349926
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349932
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349934
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349938
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349942
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349946
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349948
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349950
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349952
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349954
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349956
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349958
Principal investigator 1 Daiichi Sankyo Inc. $393.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349962
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349966
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349970
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349972
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349974
Principal investigator 1 Daiichi Sankyo Inc. $393.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349976
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349990
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349992
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349994
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349996
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350002
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350004
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350012
Principal investigator 1 Daiichi Sankyo Inc. $748.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350016
Principal investigator 1 Daiichi Sankyo Inc. $748.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350018
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350024
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350026
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350028
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350034
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350040
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350042
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350048
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350050
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350056
Principal investigator 1 Daiichi Sankyo Inc. $748.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350060
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350070
Principal investigator 1 Daiichi Sankyo Inc. $748.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350082
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350084
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350086
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350088
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350092
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350094
Principal investigator 1 Daiichi Sankyo Inc. $3,650.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350098
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350112
Principal investigator 1 Daiichi Sankyo Inc. $748.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350114
Principal investigator 1 Daiichi Sankyo Inc. $3,437.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350116
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350120
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350124
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350128
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350132
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350144
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350152
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350154
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350160
Principal investigator 1 Daiichi Sankyo Inc. $868.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350164
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350174
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350186
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350188
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350190
Principal investigator 1 Daiichi Sankyo Inc. $1,812.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350192
Principal investigator 1 TAIHO ONCOLOGY, INC. $41,275.63 11/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418531
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 11/06/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608449
Principal investigator 1 Sumitomo Pharma America, Inc. $2,800.00 11/06/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608452
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,122.20 11/05/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782108
Principal investigator 1 ABBVIE INC. $3,989.00 11/04/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202411974
Principal investigator 1 Daiichi Sankyo Inc. $19.50 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349900
Principal investigator 1 Daiichi Sankyo Inc. $57.75 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349912
Principal investigator 1 Daiichi Sankyo Inc. $100.30 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349916
Principal investigator 1 Daiichi Sankyo Inc. $8.50 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350036
Principal investigator 1 Daiichi Sankyo Inc. $125.00 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350140
Principal investigator 1 Servier BioInnovation $477.75 11/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965334
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 10/27/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415768
Principal investigator 1 TAIHO ONCOLOGY, INC. $18,565.59 10/27/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417163
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 10/23/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608447
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,855.24 10/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211417161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,090.00 10/17/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 1223266523
Principal investigator 1 TAIHO ONCOLOGY, INC. $5,237.73 10/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419973
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349902
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349910
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349918
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349922
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349928
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349964
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349978
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349980
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349984
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349986
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350000
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350030
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350038
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350046
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350054
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350058
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350064
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350068
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350072
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350078
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350090
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350104
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350106
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350108
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350110
Principal investigator 1 Daiichi Sankyo Inc. $5,355.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350130
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350142
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350146
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350148
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350150
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350158
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350162
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350166
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350168
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350170
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350176
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350180
Principal investigator 1 Daiichi Sankyo Inc. $868.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350182
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350184
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350194
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 10/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350196
Principal investigator 1 Servier BioInnovation $792.00 10/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965332
Principal investigator 1 Stemline Therapeutics Inc. $4,060.00 10/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104162
Principal investigator 1 Karyopharm Therapeutics Inc. $575.00 10/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663412
Principal investigator 1 Karyopharm Therapeutics Inc. $852.00 10/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663446
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 10/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663565
Principal investigator 1 Sumitomo Pharma America, Inc. $600.00 10/02/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608438
Principal investigator 1 Sumitomo Pharma America, Inc. $173.72 10/02/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608443
Principal investigator 1 TAIHO ONCOLOGY, INC. $750.00 10/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419995
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349906
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349960
Principal investigator 1 Daiichi Sankyo Inc. $26.55 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350006
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350010
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350102
Principal investigator 1 Daiichi Sankyo Inc. $26.55 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350126
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350134
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,713.00 10/01/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190299475
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608119
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608122
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608126
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608130
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608135
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608139
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608142
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608146
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608150
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608154
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608158
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608163
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608167
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608171
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608175
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608177
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608181
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608184
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608189
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608193
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608197
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608200
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608204
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608209
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608212
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608216
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608219
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608224
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608228
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608232
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608236
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608240
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608243
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608247
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608252
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608256
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608261
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608266
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608269
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608272
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608276
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608279
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608283
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608287
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608289
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608293
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608296
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608299
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608303
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608307
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608311
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608314
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608318
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608321
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608326
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608329
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608333
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608337
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608343
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608346
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608351
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608354
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608359
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608363
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608366
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608369
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608372
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608376
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608379
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608384
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608388
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608390
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608395
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608400
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608405
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608409
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608414
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608418
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608422
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608426
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608430
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608434
Principal investigator 1 Daiichi Sankyo Inc. $115.79 09/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349612
Principal investigator 1 TAIHO ONCOLOGY, INC. $13,231.55 09/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419985
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 09/17/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192177324
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 09/16/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608107
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 09/16/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608111
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 09/16/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608115
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,282.86 09/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211418545
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,179.08 09/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211415746
Principal investigator 1 Daiichi Sankyo Inc. $680.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349424
Principal investigator 1 Daiichi Sankyo Inc. $354.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349426
Principal investigator 1 Daiichi Sankyo Inc. $8,036.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349428
Principal investigator 1 Daiichi Sankyo Inc. $2,268.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349430
Principal investigator 1 Daiichi Sankyo Inc. $128.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349500
Principal investigator 1 Daiichi Sankyo Inc. $8,366.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349502
Principal investigator 1 Daiichi Sankyo Inc. $404.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349504
Principal investigator 1 Daiichi Sankyo Inc. $296.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349506
Principal investigator 1 Daiichi Sankyo Inc. $33,220.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349526
Principal investigator 1 Daiichi Sankyo Inc. $492.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349528
Principal investigator 1 Daiichi Sankyo Inc. $630.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349530
Principal investigator 1 Daiichi Sankyo Inc. $34,314.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349532
Principal investigator 1 Daiichi Sankyo Inc. $38,745.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349534
Principal investigator 1 Daiichi Sankyo Inc. $4,320.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349536
Principal investigator 1 Daiichi Sankyo Inc. $1,309.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349538
Principal investigator 1 Daiichi Sankyo Inc. $504.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349540
Principal investigator 1 Daiichi Sankyo Inc. $4,502.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349542
Principal investigator 1 Daiichi Sankyo Inc. $114.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349544
Principal investigator 1 Daiichi Sankyo Inc. $855.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349546
Principal investigator 1 Daiichi Sankyo Inc. $882.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349548
Principal investigator 1 Daiichi Sankyo Inc. $952.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349550
Principal investigator 1 Daiichi Sankyo Inc. $1,155.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349552
Principal investigator 1 Daiichi Sankyo Inc. $1,536.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349554
Principal investigator 1 Daiichi Sankyo Inc. $5,740.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349556
Principal investigator 1 Daiichi Sankyo Inc. $198.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349558
Principal investigator 1 Daiichi Sankyo Inc. $116.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349560
Principal investigator 1 Daiichi Sankyo Inc. $84.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349562
Principal investigator 1 Daiichi Sankyo Inc. $665.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349564
Principal investigator 1 Daiichi Sankyo Inc. $804.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349566
Principal investigator 1 Daiichi Sankyo Inc. $54,000.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349568
Principal investigator 1 Daiichi Sankyo Inc. $770.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349570
Principal investigator 1 Daiichi Sankyo Inc. $2,025.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349832
Principal investigator 1 Daiichi Sankyo Inc. $802.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349838
Principal investigator 1 Daiichi Sankyo Inc. $290.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349866
Principal investigator 1 Daiichi Sankyo Inc. $170.00 09/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349880
Principal investigator 1 Sumitomo Pharma America, Inc. $206.49 09/11/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608099
Principal investigator 1 Sumitomo Pharma America, Inc. $1,200.00 09/11/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608103
Principal investigator 1 TAIHO ONCOLOGY, INC. $78.79 09/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418543
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,076.00 09/09/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782102
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349390
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349434
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349436
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349438
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349440
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349448
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349452
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349454
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349456
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349458
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349462
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349464
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349466
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349470
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349472
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349478
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349482
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349484
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349486
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349488
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349490
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349492
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349494
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349496
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349678
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349680
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349682
Principal investigator 1 Daiichi Sankyo Inc. $3,437.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349684
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349686
Principal investigator 1 Daiichi Sankyo Inc. $1,354.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349688
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349690
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349692
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349694
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349742
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349744
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349746
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349748
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349750
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349828
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349836
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349842
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349844
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349848
Principal investigator 1 Daiichi Sankyo Inc. $748.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349854
Principal investigator 1 Daiichi Sankyo Inc. $868.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349864
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349872
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349876
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 09/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349892
Principal investigator 1 Daiichi Sankyo Inc. $261.48 09/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349398
Principal investigator 1 Daiichi Sankyo Inc. $40.62 09/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349498
Principal investigator 1 Daiichi Sankyo Inc. $500.00 09/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349738
Principal investigator 1 Daiichi Sankyo Inc. $800.00 09/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349740
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 09/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663410
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 09/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663495
Principal investigator 1 Karyopharm Therapeutics Inc. $3,202.00 09/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663537
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 09/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663555
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 09/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349608
Principal investigator 1 TAIHO ONCOLOGY, INC. $234.40 09/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211415748
Principal investigator 1 Sumitomo Pharma America, Inc. $340.00 09/02/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608096
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607596
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607600
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607604
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607607
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607611
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607616
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607620
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607623
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607627
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607631
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607634
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607638
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607641
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607645
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607648
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607652
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607656
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607660
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607664
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607669
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607671
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607674
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607677
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607681
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607686
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607689
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607693
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607696
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607700
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607704
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607707
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607713
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607717
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607721
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607726
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607729
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607733
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607736
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607740
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607744
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607749
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607753
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607757
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607761
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607765
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607770
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607774
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607777
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607780
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607784
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607788
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607792
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607797
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607801
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607805
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607809
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607813
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607817
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607821
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607825
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607830
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607833
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607837
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607841
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607844
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607847
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607851
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607855
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607859
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607863
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607867
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607871
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607875
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607879
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607884
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607888
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607892
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607895
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607900
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607904
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607907
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607912
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607916
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607920
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607925
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607929
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607932
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607937
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607941
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607945
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607949
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607953
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607956
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607960
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607964
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607967
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607971
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607975
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607979
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607984
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607988
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607991
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607996
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608000
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608003
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608007
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608011
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608015
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608019
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608023
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608026
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608030
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608034
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608038
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608042
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608045
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608049
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608053
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608057
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608061
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608065
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608069
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608072
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608076
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608080
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608084
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608088
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 09/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176608092
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,621.78 09/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414989
Principal investigator 1 Rigel Pharmaceuticals, Inc. $1,200.00 08/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249030049
Principal investigator 1 Sumitomo Pharma America, Inc. $164.69 08/28/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607592
Principal investigator 1 ABBVIE INC. $588.00 08/25/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413337
Principal investigator 1 TAIHO ONCOLOGY, INC. $250.00 08/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419241
Principal investigator 1 TAIHO ONCOLOGY, INC. $692.63 08/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211414979
Principal investigator 1 ABBVIE INC. $3,750.00 08/19/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202411971
Principal investigator 1 Ionis Pharmaceuticals, Inc. $75.00 08/18/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782099
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,800.00 08/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416442
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,085.95 08/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417141
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 08/15/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607585
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 08/15/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607589
Principal investigator 1 Sumitomo Pharma America, Inc. $491.13 08/14/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607581
Principal investigator 1 TAIHO ONCOLOGY, INC. $34,263.27 08/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211416438
Principal investigator 1 TAIHO ONCOLOGY, INC. $250.00 08/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416440
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,207.79 08/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211419237
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,122.20 08/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782095
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 08/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607572
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 08/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607577
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,427.62 08/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211414987
Principal investigator 1 Sumitomo Pharma America, Inc. $3,498.00 08/07/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607555
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 08/07/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607560
Principal investigator 1 Sumitomo Pharma America, Inc. $15,275.00 08/07/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607565
Principal investigator 1 Sumitomo Pharma America, Inc. $3,872.00 08/07/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607569
Principal investigator 1 TAIHO ONCOLOGY, INC. $183.32 08/06/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211418537
Principal investigator 1 Daiichi Sankyo Inc. $11.55 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349392
Principal investigator 1 Daiichi Sankyo Inc. $12.75 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349394
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349400
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349402
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349404
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349406
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349408
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349410
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349412
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349414
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349576
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349578
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349580
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349592
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349594
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349596
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349610
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349716
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349718
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349720
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349722
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349724
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349726
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349728
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349730
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349732
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349734
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349736
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349752
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349754
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349756
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349758
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349760
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349762
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349764
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349766
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349768
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349770
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349772
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349774
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349776
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349778
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349780
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349782
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349784
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349786
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349822
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349830
Principal investigator 1 Daiichi Sankyo Inc. $25.00 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349834
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349850
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349858
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349860
Principal investigator 1 Daiichi Sankyo Inc. $6.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349874
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349878
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349882
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349886
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349888
Principal investigator 1 Daiichi Sankyo Inc. $8.85 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349894
Principal investigator 1 GlaxoSmithKline, LLC. $2,090.00 08/05/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192177320
Principal investigator 1 Daiichi Sankyo Inc. $2,762.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349396
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349416
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349418
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349420
Principal investigator 1 Daiichi Sankyo Inc. $3,650.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349422
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349696
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349698
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349700
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349702
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349704
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349706
Principal investigator 1 Daiichi Sankyo Inc. $3,650.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349708
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349710
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349712
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349714
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349788
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349790
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349792
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349794
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349796
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349798
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349800
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349802
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349804
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349806
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349808
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349810
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349812
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349814
Principal investigator 1 Daiichi Sankyo Inc. $856.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349824
Principal investigator 1 Daiichi Sankyo Inc. $868.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349840
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349868
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 08/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349890
Principal investigator 1 Karyopharm Therapeutics Inc. $73.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663408
Principal investigator 1 Karyopharm Therapeutics Inc. $675.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663422
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663426
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663436
Principal investigator 1 Karyopharm Therapeutics Inc. $405.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663444
Principal investigator 1 Karyopharm Therapeutics Inc. $24.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663450
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663452
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663454
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663470
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663474
Principal investigator 1 Karyopharm Therapeutics Inc. $96.20 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663482
Principal investigator 1 Karyopharm Therapeutics Inc. $87.75 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663505
Principal investigator 1 Karyopharm Therapeutics Inc. $3,467.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663507
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663513
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663515
Principal investigator 1 Karyopharm Therapeutics Inc. $201.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663525
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663529
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663533
Principal investigator 1 Karyopharm Therapeutics Inc. $201.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663541
Principal investigator 1 Karyopharm Therapeutics Inc. $3,247.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663553
Principal investigator 1 Karyopharm Therapeutics Inc. $24.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663561
Principal investigator 1 Karyopharm Therapeutics Inc. $405.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663563
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663567
Principal investigator 1 Karyopharm Therapeutics Inc. $103.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663587
Principal investigator 1 Karyopharm Therapeutics Inc. $201.00 08/04/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663589
Principal investigator 1 Stemline Therapeutics Inc. $3,000.00 08/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104148
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607299
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607303
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607307
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607311
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607315
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607319
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607323
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607327
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607331
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607335
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607339
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607343
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607347
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607351
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607354
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607359
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607363
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607367
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607371
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607375
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607379
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607383
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607387
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607391
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607394
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607399
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607403
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607407
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607410
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607413
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607416
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607420
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607424
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607427
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607432
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607437
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607441
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607445
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607450
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607453
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607456
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607461
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607464
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607467
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607471
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607474
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607477
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607480
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607485
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607489
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607491
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607495
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607498
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607502
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607505
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607510
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607514
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607519
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607522
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607527
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607530
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607533
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607537
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607541
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607546
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607550
Principal investigator 1 ABBVIE INC. $588.00 07/30/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202411963
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,641.00 07/28/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782090
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,243.56 07/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416436
Principal investigator 1 Daiichi Sankyo Inc. $216.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349614
Principal investigator 1 Daiichi Sankyo Inc. $4,902.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349616
Principal investigator 1 Daiichi Sankyo Inc. $177.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349618
Principal investigator 1 Daiichi Sankyo Inc. $1,148.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349620
Principal investigator 1 Daiichi Sankyo Inc. $136.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349622
Principal investigator 1 Daiichi Sankyo Inc. $401.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349624
Principal investigator 1 Daiichi Sankyo Inc. $2,251.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349626
Principal investigator 1 Daiichi Sankyo Inc. $126.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349628
Principal investigator 1 Daiichi Sankyo Inc. $57.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349630
Principal investigator 1 Daiichi Sankyo Inc. $315.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349632
Principal investigator 1 Daiichi Sankyo Inc. $12,706.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349634
Principal investigator 1 Daiichi Sankyo Inc. $271.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349636
Principal investigator 1 Daiichi Sankyo Inc. $2,160.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349638
Principal investigator 1 Daiichi Sankyo Inc. $357.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349640
Principal investigator 1 Daiichi Sankyo Inc. $246.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349642
Principal investigator 1 Daiichi Sankyo Inc. $58.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349644
Principal investigator 1 Daiichi Sankyo Inc. $165.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349646
Principal investigator 1 Daiichi Sankyo Inc. $1,025.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349648
Principal investigator 1 Daiichi Sankyo Inc. $95.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349650
Principal investigator 1 Daiichi Sankyo Inc. $616.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349652
Principal investigator 1 Daiichi Sankyo Inc. $256.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349654
Principal investigator 1 Daiichi Sankyo Inc. $296.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349656
Principal investigator 1 Daiichi Sankyo Inc. $204.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349658
Principal investigator 1 Daiichi Sankyo Inc. $231.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349660
Principal investigator 1 Daiichi Sankyo Inc. $85.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349662
Principal investigator 1 Daiichi Sankyo Inc. $84.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349664
Principal investigator 1 Daiichi Sankyo Inc. $189.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349820
Principal investigator 1 Daiichi Sankyo Inc. $32.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349846
Principal investigator 1 Daiichi Sankyo Inc. $5,535.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349870
Principal investigator 1 Rigel Pharmaceuticals, Inc. $19,096.43 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249030037
Principal investigator 1 Rigel Pharmaceuticals, Inc. $1,200.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249030042
Principal investigator 1 Rigel Pharmaceuticals, Inc. $11,510.00 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249030047
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,178.03 07/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211414977
Principal investigator 1 Servier BioInnovation $897.00 07/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965330
Principal investigator 1 Daiichi Sankyo Inc. $2,100.00 07/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349856
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,304.45 07/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419233
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,427.62 07/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419235
Principal investigator 1 ABBVIE INC. $300.00 07/15/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413321
Principal investigator 1 TAIHO ONCOLOGY, INC. $337.50 07/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,159.00 07/11/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 1223266519
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,122.20 07/10/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782087
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104086
Principal investigator 1 Stemline Therapeutics Inc. $1,900.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104093
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104097
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104105
Principal investigator 1 Stemline Therapeutics Inc. $4,100.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104110
Principal investigator 1 Stemline Therapeutics Inc. $3,250.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104115
Principal investigator 1 Stemline Therapeutics Inc. $2,750.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104122
Principal investigator 1 Stemline Therapeutics Inc. $1,250.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104129
Principal investigator 1 Stemline Therapeutics Inc. $3,000.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104136
Principal investigator 1 Stemline Therapeutics Inc. $8,250.00 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244104142
Principal investigator 1 ABBVIE INC. $3,600.00 07/09/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413317
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349508
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349510
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349512
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349514
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349516
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349518
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349520
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349522
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349524
Principal investigator 1 Daiichi Sankyo Inc. $3,650.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349572
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349574
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349582
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349584
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349586
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349588
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349590
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349598
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349600
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349602
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349604
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349606
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349666
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349668
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349670
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349672
Principal investigator 1 Daiichi Sankyo Inc. $5,355.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349674
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349676
Principal investigator 1 Daiichi Sankyo Inc. $1,200.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349816
Principal investigator 1 Daiichi Sankyo Inc. $2,100.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349818
Principal investigator 1 Daiichi Sankyo Inc. $868.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349852
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349862
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349884
Principal investigator 1 TAIHO ONCOLOGY, INC. $89.47 07/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417135
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,437.15 07/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417823
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,187.00 07/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419979
Principal investigator 1 Daiichi Sankyo Inc. $2,100.00 07/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349432
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,250.00 07/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419231
Principal investigator 1 TAIHO ONCOLOGY, INC. $291.89 07/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211419981
Principal investigator 1 TAIHO ONCOLOGY, INC. $10,865.34 07/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417821
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 07/03/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663420
Principal investigator 1 Karyopharm Therapeutics Inc. $462.00 07/03/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663458
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 07/03/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663478
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 07/03/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663547
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414973
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414975
Principal investigator 1 TAIHO ONCOLOGY, INC. $12,757.50 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415744
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416434
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,187.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417813
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,680.50 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417815
Principal investigator 1 TAIHO ONCOLOGY, INC. $16,230.09 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417817
Principal investigator 1 TAIHO ONCOLOGY, INC. $25,879.50 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417819
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418533
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,561.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418535
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,561.00 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419227
Principal investigator 1 TAIHO ONCOLOGY, INC. $19,765.35 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419229
Principal investigator 1 TAIHO ONCOLOGY, INC. $12,757.50 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419975
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,272.45 07/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419977
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349442
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349444
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349446
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349450
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349460
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349468
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349474
Principal investigator 1 Daiichi Sankyo Inc. $31.00 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349476
Principal investigator 1 Daiichi Sankyo Inc. $31.00 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349480
Principal investigator 1 Daiichi Sankyo Inc. $8.85 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349826
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607105
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607109
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607113
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607118
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607122
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607127
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607132
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607136
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607141
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607145
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607149
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607153
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607156
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607160
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607165
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607168
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607172
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607177
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607180
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607183
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607187
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607191
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607195
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607200
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607204
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607207
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607211
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607214
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607217
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607223
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607227
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607231
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607233
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607238
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607241
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607245
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607250
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607254
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607258
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607262
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607266
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607271
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607275
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607279
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607283
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607287
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607291
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 07/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607295
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 06/27/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607098
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 06/27/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607102
Principal investigator 1 GlaxoSmithKline, LLC. $5,076.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192175473
Principal investigator 1 Genmab U.S., Inc. $400.00 06/24/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930300
Principal investigator 1 TAIHO ONCOLOGY, INC. $46,711.76 06/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416448
Principal investigator 1 TAIHO ONCOLOGY, INC. $90.39 06/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211417159
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 06/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211419253
Principal investigator 1 Daiichi Sankyo Inc. $250.00 06/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350633
Principal investigator 1 Genmab U.S., Inc. $756.95 06/19/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930304
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,122.20 06/19/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246782081
Principal investigator 1 ABBVIE INC. $2,800.00 06/18/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413313
Principal investigator 1 Sumitomo Pharma America, Inc. $5,854.00 06/18/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607093
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,200.00 06/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419989
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,194.47 06/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211417837
Principal investigator 1 Sumitomo Pharma America, Inc. $2,376.00 06/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607087
Principal investigator 1 Sumitomo Pharma America, Inc. $1,023.00 06/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607090
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349250
Principal investigator 1 Daiichi Sankyo Inc. $868.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349252
Principal investigator 1 Daiichi Sankyo Inc. $868.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349254
Principal investigator 1 Daiichi Sankyo Inc. $868.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349256
Principal investigator 1 Daiichi Sankyo Inc. $4,259.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349258
Principal investigator 1 Daiichi Sankyo Inc. $868.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349260
Principal investigator 1 Daiichi Sankyo Inc. $3,437.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349262
Principal investigator 1 Daiichi Sankyo Inc. $3,437.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349264
Principal investigator 1 Daiichi Sankyo Inc. $868.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349266
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349294
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349296
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349332
Principal investigator 1 Daiichi Sankyo Inc. $393.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349334
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349336
Principal investigator 1 Daiichi Sankyo Inc. $3,143.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349338
Principal investigator 1 Daiichi Sankyo Inc. $3,235.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349340
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349342
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349350
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349352
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349356
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349358
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349360
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349362
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349364
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349370
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349374
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349378
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349384
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349386
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349388
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,800.00 06/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419987
Principal investigator 1 TAIHO ONCOLOGY, INC. $300.00 06/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415760
Principal investigator 1 ABBVIE INC. $4,370.08 06/05/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413310
Principal investigator 1 Genmab U.S., Inc. $960.00 06/05/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930287
Principal investigator 1 Genmab U.S., Inc. $4,400.00 06/05/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/05/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES No dispute reported 06/30/2026 1223266517
Principal investigator 1 TAIHO ONCOLOGY, INC. $172,901.25 06/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419251
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 06/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663414
Principal investigator 1 Karyopharm Therapeutics Inc. $462.00 06/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663448
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 06/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663539
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 06/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663549
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 06/02/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663583
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,621.78 06/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414993
Principal investigator 1 Rigel Pharmaceuticals, Inc. $61,023.95 05/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029901
Principal investigator 1 Rigel Pharmaceuticals, Inc. $4,370.00 05/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029904
Principal investigator 1 Rigel Pharmaceuticals, Inc. $3,000.00 05/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029909
Principal investigator 1 Sumitomo Pharma America, Inc. $800.00 05/29/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607083
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,500.00 05/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 05/26/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES No dispute reported 06/30/2026 1223266513
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,054.19 05/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417153
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,747.56 05/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418559
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,600.00 05/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419249
Principal investigator 1 ABBVIE INC. $1,350.00 05/20/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413290
Principal investigator 1 ABBVIE INC. $55,944.01 05/20/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413294
Principal investigator 1 ABBVIE INC. $2,400.00 05/20/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413297
Principal investigator 1 ABBVIE INC. $895.00 05/20/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413302
Principal investigator 1 ABBVIE INC. $3,146.85 05/20/2025 Covered Recipient Teaching Hospital
JFK UNIVERSITY MEDICAL CENTER
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202413306
Principal investigator 1 Rigel Pharmaceuticals, Inc. $2,000.00 05/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029913
Principal investigator 1 Rigel Pharmaceuticals, Inc. $3,000.00 05/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029921
Principal investigator 1 Rigel Pharmaceuticals, Inc. $1,800.00 05/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029924
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,508.22 05/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211419993
Principal investigator 1 Daiichi Sankyo Inc. $3,864.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349280
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349282
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349284
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349286
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349288
Principal investigator 1 Daiichi Sankyo Inc. $868.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349290
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349298
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349300
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349302
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349304
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349306
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349308
Principal investigator 1 Daiichi Sankyo Inc. $3,518.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349310
Principal investigator 1 Daiichi Sankyo Inc. $748.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349312
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349314
Principal investigator 1 Daiichi Sankyo Inc. $3,437.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349316
Principal investigator 1 Daiichi Sankyo Inc. $1,812.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349318
Principal investigator 1 Daiichi Sankyo Inc. $1,609.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349320
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349322
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349324
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349326
Principal investigator 1 Daiichi Sankyo Inc. $1,812.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349328
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349330
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349368
Principal investigator 1 Daiichi Sankyo Inc. $1,170.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349376
Principal investigator 1 Daiichi Sankyo Inc. $748.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349380
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349382
Principal investigator 1 Sumitomo Pharma America, Inc. $250.00 05/08/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607079
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 05/05/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663442
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 05/05/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663468
Principal investigator 1 Karyopharm Therapeutics Inc. $9,404.00 05/05/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663493
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 05/05/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663577
Principal investigator 1 Daiichi Sankyo Inc. $250.00 05/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349354
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,559.00 05/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211415766
Principal investigator 1 Servier BioInnovation $1,033.50 05/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965328
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606638
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606642
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606647
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606653
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606657
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606662
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606665
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606669
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606673
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606677
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606681
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606685
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606689
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606693
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606697
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606701
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606704
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606707
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606711
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606714
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606717
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606721
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606725
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606729
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606734
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606738
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606742
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606746
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606751
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606755
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606759
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606763
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606766
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606770
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606774
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606778
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606781
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606785
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606790
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606794
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606798
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606801
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606805
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606808
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606814
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606817
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606821
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606825
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606829
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606833
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606838
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606843
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606847
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606850
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606855
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606857
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606861
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606864
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606868
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606872
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606876
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606880
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606885
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606889
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606894
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606898
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606903
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606908
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606912
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606917
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606920
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606923
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606927
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606931
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606934
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606939
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606942
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606947
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606951
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606955
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606958
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606963
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606967
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606970
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606974
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606979
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606982
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606984
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606988
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606991
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606994
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606999
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607002
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607006
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607010
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607013
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607016
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607020
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607025
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607028
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607032
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607036
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607040
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607044
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607049
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607053
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607057
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607061
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607066
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607071
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 05/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176607076
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,800.00 04/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414991
Principal investigator 1 TAIHO ONCOLOGY, INC. $49,964.90 04/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418557
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,209.61 04/24/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocyt No dispute reported 06/30/2026 1190307231
Principal investigator 1 Sumitomo Pharma America, Inc. $30,550.00 04/24/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606634
Principal investigator 1 TAIHO ONCOLOGY, INC. $58,351.18 04/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211417157
Principal investigator 1 ABBVIE INC. $1,726.00 04/17/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy No dispute reported 06/30/2026 1202411931
Principal investigator 1 Genmab U.S., Inc. $500.00 04/17/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930284
Principal investigator 1 TAIHO ONCOLOGY, INC. $13,122.00 04/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417833
Principal investigator 1 TAIHO ONCOLOGY, INC. $27,615.03 04/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418555
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,885.00 04/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211415764
Principal investigator 1 TAIHO ONCOLOGY, INC. $21,219.30 04/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417149
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,561.00 04/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417151
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,623.50 04/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419247
Principal investigator 1 Daiichi Sankyo Inc. $868.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349268
Principal investigator 1 Daiichi Sankyo Inc. $868.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349270
Principal investigator 1 Daiichi Sankyo Inc. $868.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349272
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349274
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349276
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349278
Principal investigator 1 Daiichi Sankyo Inc. $4,167.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349292
Principal investigator 1 Daiichi Sankyo Inc. $3,650.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349344
Principal investigator 1 Daiichi Sankyo Inc. $1,285.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349346
Principal investigator 1 Daiichi Sankyo Inc. $5,355.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349348
Principal investigator 1 Daiichi Sankyo Inc. $250.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349366
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349372
Principal investigator 1 TAIHO ONCOLOGY, INC. $76.52 04/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417147
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663416
Principal investigator 1 Karyopharm Therapeutics Inc. $1,500.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663428
Principal investigator 1 Karyopharm Therapeutics Inc. $250.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663432
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663456
Principal investigator 1 Karyopharm Therapeutics Inc. $2,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663460
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663466
Principal investigator 1 Karyopharm Therapeutics Inc. $2,720.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663480
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663486
Principal investigator 1 Karyopharm Therapeutics Inc. $4,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663488
Principal investigator 1 Karyopharm Therapeutics Inc. $1,900.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663501
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663509
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663521
Principal investigator 1 Karyopharm Therapeutics Inc. $3,000.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663527
Principal investigator 1 Karyopharm Therapeutics Inc. $2,720.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663531
Principal investigator 1 Karyopharm Therapeutics Inc. $6,450.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663535
Principal investigator 1 Karyopharm Therapeutics Inc. $1,500.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663543
Principal investigator 1 Karyopharm Therapeutics Inc. $3,100.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663575
Principal investigator 1 Karyopharm Therapeutics Inc. $2,550.00 04/07/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663579
Principal investigator 1 Genmab U.S., Inc. $19,496.50 04/04/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930292
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,860.00 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415754
Principal investigator 1 TAIHO ONCOLOGY, INC. $242.57 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415756
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,255.50 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415758
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,561.00 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417831
Principal investigator 1 TAIHO ONCOLOGY, INC. $18,351.00 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418549
Principal investigator 1 TAIHO ONCOLOGY, INC. $30,388.50 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418551
Principal investigator 1 TAIHO ONCOLOGY, INC. $270.00 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418553
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,200.00 04/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419245
Principal investigator 1 TAIHO ONCOLOGY, INC. $8,976.15 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416444
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,500.00 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416446
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,200.00 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417143
Principal investigator 1 TAIHO ONCOLOGY, INC. $14,015.70 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417145
Principal investigator 1 TAIHO ONCOLOGY, INC. $281.54 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417829
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,374.00 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418547
Principal investigator 1 TAIHO ONCOLOGY, INC. $19,575.00 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419243
Principal investigator 1 TAIHO ONCOLOGY, INC. $750.00 04/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211419991
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606501
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606504
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606507
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606511
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606514
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606518
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606522
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606526
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606530
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606533
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606537
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606540
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606544
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606547
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606551
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606555
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606559
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606563
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606567
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606571
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606575
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606581
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606584
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606587
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606591
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606595
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606598
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606603
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606607
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606610
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606615
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606619
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606623
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 04/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606626
Principal investigator 1 Stemline Therapeutics Inc. $237.62 03/25/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244119022
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,689.00 03/24/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES No dispute reported 06/30/2026 1223266511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,639.00 03/21/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES No dispute reported 06/30/2026 1223266509
Principal investigator 1 Stemline Therapeutics Inc. $10.60 03/18/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244118990
Principal investigator 1 Stemline Therapeutics Inc. $85.99 03/18/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244118996
Principal investigator 1 Stemline Therapeutics Inc. $175.82 03/18/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244119002
Principal investigator 1 Stemline Therapeutics Inc. $20.90 03/18/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244119009
Principal investigator 1 Stemline Therapeutics Inc. $46.60 03/18/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244119016
Principal investigator 1 TAIHO ONCOLOGY, INC. $364,605.57 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211414985
Principal investigator 1 TAIHO ONCOLOGY, INC. $250.00 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419983
Principal investigator 1 Daiichi Sankyo Inc. $12,800.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350214
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350216
Principal investigator 1 Daiichi Sankyo Inc. $1,900.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350218
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350220
Principal investigator 1 Daiichi Sankyo Inc. $1,750.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350222
Principal investigator 1 Daiichi Sankyo Inc. $1,250.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350224
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 03/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350228
Principal investigator 1 ABBVIE INC. $2,100.00 03/13/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202411909
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350198
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350200
Principal investigator 1 Daiichi Sankyo Inc. $3,029.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350202
Principal investigator 1 Daiichi Sankyo Inc. $5,748.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350204
Principal investigator 1 Daiichi Sankyo Inc. $3,538.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350206
Principal investigator 1 Daiichi Sankyo Inc. $3,447.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350208
Principal investigator 1 Daiichi Sankyo Inc. $1,904.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350210
Principal investigator 1 Daiichi Sankyo Inc. $2,489.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350212
Principal investigator 1 Daiichi Sankyo Inc. $3,425.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223350226
Principal investigator 1 Genmab U.S., Inc. $9,700.00 03/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930272
Principal investigator 1 Genmab U.S., Inc. $4,800.00 03/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930280
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 03/06/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663430
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 03/06/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663476
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349126
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349128
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349130
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349132
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349134
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349136
Principal investigator 1 Daiichi Sankyo Inc. $57.75 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349138
Principal investigator 1 Daiichi Sankyo Inc. $69.30 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349140
Principal investigator 1 Daiichi Sankyo Inc. $150.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349142
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349144
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349146
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349148
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349150
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349152
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349154
Principal investigator 1 Daiichi Sankyo Inc. $150.45 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349156
Principal investigator 1 Daiichi Sankyo Inc. $24.95 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349158
Principal investigator 1 Daiichi Sankyo Inc. $17.70 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349160
Principal investigator 1 Daiichi Sankyo Inc. $17.70 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349162
Principal investigator 1 Daiichi Sankyo Inc. $17.70 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349164
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349166
Principal investigator 1 Daiichi Sankyo Inc. $34.65 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349168
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349170
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349172
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349174
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349176
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349178
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349180
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349182
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349184
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349186
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349188
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349190
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349192
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349194
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349196
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349198
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349200
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349202
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349204
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349206
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349208
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349210
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349212
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349214
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349216
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349218
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349220
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349222
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349224
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349226
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349228
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349230
Principal investigator 1 Daiichi Sankyo Inc. $12.75 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349232
Principal investigator 1 Daiichi Sankyo Inc. $124.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349234
Principal investigator 1 Daiichi Sankyo Inc. $124.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349236
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349238
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349240
Principal investigator 1 Daiichi Sankyo Inc. $62.00 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349242
Principal investigator 1 Daiichi Sankyo Inc. $17.70 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349244
Principal investigator 1 Daiichi Sankyo Inc. $35.40 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349246
Principal investigator 1 Daiichi Sankyo Inc. $26.55 03/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
AC220-168 No dispute reported 06/30/2026 1223349248
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606319
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606323
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606327
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606331
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606336
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606339
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606343
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606347
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606350
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606353
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606358
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606361
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606365
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606367
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606371
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606374
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606378
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606382
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606386
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606392
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606395
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606401
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606404
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606408
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606412
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606414
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606417
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606420
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606424
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606429
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606432
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606439
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606443
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606447
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606451
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606455
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606460
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606464
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606467
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606470
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606473
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606478
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606481
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606486
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606490
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606492
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 03/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606496
Principal investigator 1 Servier BioInnovation $2,304.00 02/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965326
Principal investigator 1 TAIHO ONCOLOGY, INC. $21,824.88 02/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211417155
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56,050.95 02/21/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 1223266507
Principal investigator 1 TAIHO ONCOLOGY, INC. $20,346.85 02/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415752
Principal investigator 1 TAIHO ONCOLOGY, INC. $7,381.29 02/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211418561
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/14/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL CENTER
EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS No dispute reported 06/30/2026 1192175478
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,563.30 02/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211415750
Principal investigator 1 Sumitomo Pharma America, Inc. $1,200.00 02/13/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606315
Principal investigator 1 Karyopharm Therapeutics Inc. $1,593.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663418
Principal investigator 1 Karyopharm Therapeutics Inc. $462.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663424
Principal investigator 1 Karyopharm Therapeutics Inc. $2,726.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663462
Principal investigator 1 Karyopharm Therapeutics Inc. $5,631.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663497
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663511
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663517
Principal investigator 1 Karyopharm Therapeutics Inc. $11,328.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663523
Principal investigator 1 Karyopharm Therapeutics Inc. $2,053.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663559
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663571
Principal investigator 1 Karyopharm Therapeutics Inc. $2,520.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663573
Principal investigator 1 Karyopharm Therapeutics Inc. $2,053.00 02/12/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663585
Principal investigator 1 Servier BioInnovation $1,436.50 02/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965324
Principal investigator 1 Rigel Pharmaceuticals, Inc. $2,750.00 02/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
C-906289-002 No dispute reported 06/30/2026 1249029917
Principal investigator 1 Sumitomo Pharma America, Inc. $2,602.00 01/30/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606311
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,800.00 01/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211416450
Principal investigator 1 Genmab U.S., Inc. $7,625.51 01/23/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930268
Principal investigator 1 Sumitomo Pharma America, Inc. $3,200.00 01/23/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606307
Principal investigator 1 TAIHO ONCOLOGY, INC. $175.19 01/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417139
Principal investigator 1 TAIHO ONCOLOGY, INC. $306.31 01/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418541
Principal investigator 1 Servier BioInnovation $1,972.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION No dispute reported 06/30/2026 1235965322
Principal investigator 1 Karyopharm Therapeutics Inc. $535.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663434
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663438
Principal investigator 1 Karyopharm Therapeutics Inc. $87.75 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663440
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663464
Principal investigator 1 Karyopharm Therapeutics Inc. $462.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663472
Principal investigator 1 Karyopharm Therapeutics Inc. $675.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663484
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663499
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663503
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663519
Principal investigator 1 Karyopharm Therapeutics Inc. $81.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663545
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663551
Principal investigator 1 Karyopharm Therapeutics Inc. $165.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663557
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663569
Principal investigator 1 Karyopharm Therapeutics Inc. $527.00 01/20/2025 Non-covered Recipient Entity
Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246663581
Principal investigator 1 ABBVIE INC. $2,706.25 01/16/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202411877
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,582.38 01/06/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
ASTX727-07 No dispute reported 06/30/2026 1211415762
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,113.65 01/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blo No dispute reported 06/30/2026 1236001116
Principal investigator 1 Genmab U.S., Inc. $445.39 01/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. No dispute reported 06/30/2026 1235930276
Principal investigator 1 Novartis Pharmaceuticals Corporation $369,460.21 01/01/2025 Non-covered Recipient Entity
HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190307223
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606153
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606156
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606160
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606164
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606167
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606171
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606175
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606179
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606183
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606187
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606191
Principal investigator 1 Sumitomo Pharma America, Inc. $95.50 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606197
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606201
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606205
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606209
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606212
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606215
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606219
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606223
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606227
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606230
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606236
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606239
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606242
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606247
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606250
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606252
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606258
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606262
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606265
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606269
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606273
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606277
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606280
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606284
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606287
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606291
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606294
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606297
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176606303